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Abstract: Adenosine is a neuromodulator with several functions in the central nervous system (CNS), such as inhibition of neuronal 
activity in many signaling pathways. Most of the sedating, anxiolytic, seizure-inhibiting and protective actions of adenosine are mediated 
by adenosine A1 receptors (A1R) on the surface of neurons and glia. Positron Emission Tomography (PET) is a powerful in vivo imaging 
tool which can be applied to investigate the physiologic and pathologic roles of A1R in the human brain, and to elucidate the mechanism 
of action of therapeutic drugs targeting adenosine receptors, nucleoside transporters and adenosine-degrading enzymes. In this review 
article, we discuss (i) functions of adenosine and its receptors in cerebral metabolism; (ii) radioligands for A1R imaging: xanthine 
antagonists, non-xanthine antagonists, and agonists; (iii) roles of A1R in health and disease, viz. sleep-wake regulation, modulation of 
memory retention and retrieval, mediating the effects of alcohol consumption, protecting neurons during ischemia and reperfusion, 
suppression of seizures, modulating neuroinflammation and limiting brain damage in neurodegenerative disorders. The application of 
PET imaging could lead to novel insights in these areas. Finally (iv), we discuss the application of PET in pharmacodynamic studies and 
we examine therapeutic applications of adenosine kinase inhibitors, e.g. in the treatment of pain, inflammation, and epilepsy.  
Keywords: Adenosine, Alcohol Abuse, Alzheimer Disease, Brain, Drug Development, Epilepsy, Inflammation, Multiple Sclerosis, Pain, 
Parkinson’s Disease, Positron Emission Tomography, Receptor Imaging, Sleep, Stroke. 
1. INTRODUCTION 
 1.1. Sources, Regulation and Fate of Extracellular Adenosine 
The purine nucleoside adenosine is not a classical signaling 
substance, as adenosine is neither stored nor released from vesicles. 
The nucleoside plays a neuromodulatory role by affecting the 
excitability of neurons that release neurotransmitters such as 
glutamate, -amino butyric acid (GABA), acetylcholine and 
dopamine [1-12]. Adenosine is involved in homeostatic reduction 
of cellular excitability during stress and trauma via its interaction 
with receptors on the cell surface. Moreover, adenosine is involved 
in the regulation of synaptic plasticity. Balanced activation of 
inhibitory and facilitatory adenosine receptors modulates long term 
potentiation (e.g., in the hippocampus) [13-15]. 
Metabolic pathways involved in the formation and removal of 
adenosine are presented in Fig. (1). Extracellular adenosine may 
originate from intracellular adenosine - which can pass the plasma 
membrane via an equilibrative nucleoside transporter (ENT), or by 
hydrolysis of locally released adenine nucleotides such as 
adenosine triphosphate (ATP), adenosine diphosphate (ADP), 
adenosine monophosphate (AMP) and to a lesser extent cyclic 
adenosine monophosphate (cAMP). Production of extracellular 
adenosine is the result of the breakdown of such nucleotides by 
ecto-nucleotidases [16-18]. The rate-limiting step is the conversion 
of AMP to adenosine which is catalyzed by ecto-5’-nucleotidase 
(CD73). The biochemical and pharmacological properties of this 
enzyme have been extensively characterized [16,19]. 5’-
Nucleotidase is inhibited by ATP and ADP [18]. The quantititative 
importance of this mechanism has been confirmed by a kinetic 
characterization of the breakdown of extracellular ATP at the 
cholinergic striatal synapse [20]. 
Extracellular adenosine is subject to metabolic degradation by 
adenosine deaminase (ADA) which results in the formation of 
inosine [21]. Another route of adenosine inactivation is the 
reversible reaction catalyzed by S-adenosyl homocysteine (SAH) 
hydrolase [22]. Formation of SAH from adenosine and 
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homocysteine is restricted since homocysteine levels are rate-
limiting. In the brain, the SAH pathway is a quantitatively 
negligible pathway of adenosine catabolism [23]. The major route 
of adenosine removal under normal conditions is phosphorylation 
to AMP by adenosine kinase (AK). 
1.2. Classification of Adenosine Receptors  
The adenosine receptor (AR) family consists of the A1, A2A, 
A2B and A3 subtypes (A1R. A2AR, A2BR and A3R, respectively). 
A1R and A3R inhibit whereas A2AR and A2BR stimulate production 
of the second messenger, cAMP. A1R and A2AR are activated by 
nanomolar concentrations of adenosine whereas A2BR and A3R 
become activated only when adenosine levels rise into the 
micromolar range during inflammation, hypoxia or ischemia [24-
26]. The four AR subtypes from rat, mouse, human and other 
species have been pharmacologically recognized, cloned, purified 
and expressed [27-29]. In the following pages, we will focus on the 
A1R and the potential contribution of positron emission tomography 
(PET) imaging to the study of its involvement in physiological 
processes. 
1.3. Regional Distribution and Signaling of A1R 
The A1R is the most strongly preserved AR subtype among 
different animal species [28]. A1Rs exhibit the highest affinities for 
adenosine and synthetic agonists of all AR subtypes [30]. They are 
distributed throughout the body and are also highly expressed in the 
brain, especially in hippocampus, frontal cortex, thalamic nuclei, 
basal ganglia and dorsal horn of the spinal cord. Peripheral organs 
with high A1R expression include eye, adrenal gland, heart and 
aorta.  
The regional distributions of A1R in human and rodent brains 
are similar but not completely identical. In human cerebellum, A1R 
densities are low in contrast to rat cerebellum, where moderate A1R 
expression is noted [31-36]. Different neurons express different 
levels of A1R. In rat brain, the highest A1R immunoreactivity is 
observed in pyramidal neurons of layer 5 of the cerebral cortex, and 
in pyramidal cells in fields CA2 and CA3 of the hippocampus. In 
layer 5, immunoreactivity is detected in cell bodies, dendrites and 
initial segments of axons [37].  
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Activation of A1Rs inhibits adenylyl cyclase, closes voltage-
dependent Ca
2+
 channels, and activates K
+
 channels. Signalling of 
this AR subtype occurs through Gi/o pathways in various cells 
(including neurons). As a result, the neuronal activity is suppressed 
[38,39]. In presynaptic regions, adenosine inhibits neurotransmitter 
and neuropeptide release, including the release of glutamate, 
substance P and calcitonin gene related peptide [40]. In 
postsynaptic areas, adenosine abolishes sensory transmission and 
causes membrane hyperpolarisation [41,42]. 
2. RADIOLIGANDS FOR A1R IMAGING 
PET is a medical imaging technique providing information on 
tissue biochemistry rather than anatomy. PET imaging has several 
unique properties: high sensitivity, low radiation dose, possibility to 
correct data for attenuation and scatter (thus quantitative), 
radioactive labeling of natural substances or drugs with high 
specific radioactivity so that these can be used as tracers to monitor 
the pharmacokinetics of the non-radioactive compounds. PET may 
therefore be applied to measure regional AR densities in the living 
human brain and the dose-dependent occupancy of cerebral AR by 
therapeutic drugs. A comprehensive overview of PET tracers for 
the different AR subtypes has been presented in some recent 
reviews [43,44]. 
Several ligands for PET imaging of A1R have been prepared 
(see Table 1 and Fig. 2). These include xanthine A1R antagonists, 
non-xanthine A1R antagonists and A1R agonists. All compounds 





F]CPFPX. Both can be applied for PET 
studies of cerebral A1R in humans. The long physical half life of 
18
F 
(109.8 min) as compared to 
11
C (20.4 min) allows longer scanning 
times with [
18
F]CPFPX than with [
11
C]MPDX. Because of this 
difference in half life, [
18
F]CPFPX can be distributed to remote 
imaging sites without cyclotron facilities, in contrast to 
[
11
C]MPDX. However, the radiation dose that subjects will receive 
after injection of [
18
F]CPFPX (300 MBq) is greater that that of 
[
11
C]MPDX (300 MBq): 5.3 mSv vs. 1.05 mSv, respectively ([45] 
and Ishiwata, unpublished data). Thus, multiple-injection protocols 
are possible with [
11
C]MPDX but not with [
18
F]CPFPX. Since each 
tracer has specific advantages and disadvantages, tracer selection 
will be based on historic interest and the facilities at one’s disposal 
rather than on clear superiority of a certain compound. 
Efforts to develop A1R ligands for PET with improved 
properties might focus on antagonists with reduced lipophilicity and 
improved water solubility, e.g. compounds with non-xanthine 
structures. However, the first reported example of such tracers, 
[
11






3. PHYSIOLOGICAL ROLE OF A1R AND CHANGES OF 
A1R EXPRESSION IN DISORDERS OF THE CNS 
3.1. Sleep-Wake Regulation 
Adenosine plays an important role in the induction of sleep 
after prolonged wakefulness [47]. Prolonged wakefulness with its 
associated prolonged neuronal activity increases extracellular 
adenosine levels in the forebrain of conscious cats, whereas these 
levels diminish during sleep [48]. A [
18
F]CPFPX-PET study in 
humans has indicated that in addition to changes of extracellular 
adenosine, A1R are upregulated in cortical and subcortical regions 
of the brain after prolonged wakefulness (max. 15.3%), which 
suggests that changes of A1R expression are contributing to 
homeostatic sleep regulation [49]. Short periods of total sleep 























Fig. (1). Metabolic scheme showing the pathways of adenosine formation and removal. Enzymes involved are: 1. ATPases, 2. oxidative phosporylation (and 
creatine kinase), 3. adenylyl cyclase, 4. adenylate kinase, 5. phosphodiesterase, 6. 5’-nucleotidase, 7. adenosine kinase, 8. SAH hydrolase, 9. ecto-5’-
nucleotidase (CD73), 10. adenosine deaminase. 
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Table 1. Development of Radioligands for PET Imaging of A1R 
 
Ligand A1R affinity Studies performed Findings References 





3.0 nM (Ki) Biodistribution study in 
mice 
Ex vivo autoradiography 
(mice/rats) 
PET study in anesthetized 
monkeys 
About 57% specific binding (to A1R not A2R) 
Tracer distribution in brain reflects regional A1R density 
Decreased binding in superior colliculus after unilateral eye removal 
Tracer distribution in brain reflects regional A1R density 





1.7 nM (Ki) Biodistribution study in 
mice 




4.2 nM (Ki) Biodistribution study in 
mice 
Metabolite analysis in 
mice 




PET study in anesthetized 
cats 
PET study in anesthetized 
monkey 
Human PET study  
(healthy volunteers) 
Initial brain uptake higher than EPDX and KF15372 but faster washout. 
Dosimetry data indicate acceptable radiation dose in human studies. 
Metabolites appear in plasma but brain activity is mainly parent at 30 
min. 
Decreased binding in superior colliculus after unilateral eye removal. 
About 55% specific binding (to A1R not A2R). 
In animal model of dystonia, tracer binding in hippocampus is 
decreased. 
--- 
Distribution volume of tracer in brain reflects regional A1R density. 
Bound tracer can be displaced by an excess of cold A1R antagonist. 
In a cat model of stroke, losses of A1R can be detected in ischemic areas. 
The magnitude of these losses indicates severity of the insult and  
predicts subsequent complications (including mortality). 
Good brain uptake, distribution reflects regional A1R density. 
Tracer distribution in brain reflects regional A1R density. 
Pattern differs from that of a flow tracer or a glucose analog. 
Distribution volume (Logan plot) or binding potential (compartment  



















4.4 nM (Kd 
rat) 
 
Biodistribution study in 
mice 
Metabolite analysis in 
mice 
Ex vivo autoradiography 
(rats) 
Animal PET study in rats 
Human PET study 
(healthy volunteers) 
Metabolite study (liver  
microsomes) 
Distribution in brain reflects regional A1R density. 
Metabolites appear in plasma but brain activity is mainly parent at 60 
min. 
About 70% of brain uptake is specific (to A1R) and reversible. 
Tracer distribution in brain reflects regional A1R density (>90% 
specific). 
Brain well-visualized, bound tracer can be displaced by A1R antagonist. 
Tracer distribution in brain reflects regional A1R density. 
Tracer kinetics in human brain are appropriate for quantititative imaging. 
Distribution volume (Logan plot) or binding potential (compartment  
model analysis) can be used for quantification purposes. 
Simplified study protocols are possible (venous rather than arterial blood 
sampling, bolus-infusion or single bolus administration of the tracer). 
Short scanning protocols (60 min) are possible in humans. 
Bound tracer can be displaced by cold CPFPX in all brain regions. 
Non-invasive procedure (reference tissue model) is suitable for 
quantification of A1R in human brain.  
Tracer is metabolized by cytochrome CYP1A2. 














0.8-7.9 nM  
(Kd rat, pig 
cortex) 
Ex vivo autoradiography 
(rats) 
Tracer binding is largely nonspecific. 
Thus, this ligand is not suitable for imaging purposes. 
The iodine radiolabeling results also in loss of selectivity for the A1R. 
[277] 





2.9 nM (Ki) Ex vivo autoradiography 
(rats) 
PET study in conscious 
monkeys 
Tracer distribution in brain reflects regional A1R density. 
About 50% specific binding (to A1R not A2R). 




Agonists     
5-O-(methyl[75Se]seleno)- 
N6-cyclopentyladenosine 











No in vivo data reported 
May bind not only to A1R but also to other AR subtypes 
[279] 
1This compound was prepared for Single Photon Emission Computed Tomography (SPECT) rather than PET imaging. 

















[11C]KF15372        R1=[
11C]propyl, R2=H
[11C]EPDX             R1=[
11C]ethyl, R2=H











Fig. (2). Antagonist radioligands for PET imaging of A1R. 
detectable increases of A1R expression in rat brain [50]. However, 
longer periods of total sleep deprivation in rodents (12 or 24 h) are 
accompanied by a significant upregulation of A1R (up to 14%) in 
various brain areas [51,52]. [
3
H]Phenylisopropyladenosine (PIA, 
Fig. 3) saturation binding assays have indicated that A1R densities 
in cortical and subcortical regions of rat brain are increased not only 
after total sleep deprivation, but also after 48 and 96 h of partial, 
rapid eye movement (REM) sleep deprivation, whereas affinity (Kd) 
values for agonist binding are not significantly altered [53]. After 
restriction of sleep and also after performance of a difficult learning 
task, cerebral synchronized slow wave activity (SWA) is enhanced 
during the next sleeping period, and this activity is related to the 
subsequent improvement of cognitive performance [54,55]. 
Activation of A1R is necessary for the increase of SWA. If this 
increase is impaired (e.g. because of knockout of the A1R gene) 
animals fail to maintain normal cognitive function. Thus, adenosine 
appears to be an important homeostatic sleep factor, and A1Rs are 
involved in the regulation of sleep. 
After administration of a selective A1R agonist, N6-
Cyclopentyladenosine (CPA, Fig. 3), either by the systemic or the 
cerebroventricular route, SWA increased in rats during non-REM 
sleep [56]. Such stimulation of A1R mimics the effect of total sleep 
deprivation in rodents. A similar effect on sleep is observed when 
extracellular adenosine levels in the mammalian brain are raised by 
administering inhibitors of nucleoside transport [57]. When levels 
of extracellular adenosine in the basal forebrain are raised by 
microdialysis, vigilance of rats is significantly impaired [58]. This 
effect on vigilance is completely blocked after co-administration of 
a selective A1R antagonist, 8-cyclopentyltheophylline (CPT, Fig. 
3), with adenosine [58]. On the other hand, infusion of CPT into 
the basal forebrain diminishes the sleeping ability (both slow-wave 
and REM sleep) of cats [57]. Infusion of A1R antisense in the 
cholinergic basal forebrain of rats inhibits the translation of A1R 
mRNA, resulting in decreased non-REM sleep and increased 
wakefulness [59]. Such pharmacological experiments have 
provided additional support for the important role of A1R in sleep 
regulation. Agonists for this receptor usually promote [60-62] while 
antagonists diminish [60,63] sleep.  
In rat brain, prolonged wakefulness with accompanying 
increases of extracellular adenosine and stimulation of A1R 
increases the activity of the transcription factor NF-kappaB [64,65]. 
This transcription factor regulates expression of several modulatory 
substances, such as interleukin-1-ß and tumor necrosis factor , 
which shows a diurnal rhythm. Some effects of adenosine on sleep 
homeostasis, particularly the phenomenon of “sleep debt” may be 
triggered via this mechanism.  
Orexinergic neurons in the lateral hypothalamus also express 
A1R [66]. Adenosine and A1R agonists inhibit activity of the 
hypocretin/orexin neurons in this area via A1R which promotes 
sleep [67,68]. On the other hand, blockade of A1R in such neurons 
causes a pronounced increase in wakefulness [68,69]. Adenosine 
reduces the frequency of action potentials in hypocretin/orexin 
neurons by depressing excitatory synaptic transmission to these 
cells. An additional mechanism involved in the sleep-promoting 
effects of adenosine may be suppression of the activity of 
histaminergic neurons in the tuberomammillary nucleus via A1R 
[70]. Thus, in addition to its effects in basal forebrain, adenosine 
promotes sleep by reducing the activity of orexinergic and 
histaminergic neurons in the hypothalamus [67]. 
An additional brain region involved in sleep regulation is the 
pontine reticular formation. Microinjection of the A1R agonist N6-
cyclopentyladenosine (CPA) or inhibition of the formation of 
cAMP in this area increases REM sleep [71]. Another study has 
shown that administration of an A1R agonist (N6-p-
sulfophenyladenosine) decreases the (arousal-promoting) release of 
the neurotransmitter acetylcholine and increases the recovery time 
from halothane anesthesia [7]. 
Neurons in the previously mentioned brain areas are wake-
active. Thus, suppression of their activity via stimulation of A1R 
promotes sleep. In contrast to the regions mentioned above, the 
lateral preoptic area of rat hypothalamus is an area with an 
abundance of sleep-active neurons. A1R agonists and the adenosine 
transport inhibitor 4-nitrobenzyl-thioinosine have opposite effects 
in this area as in other regions of the brain, i.e. they increase 
wakefulness rather than sleep [72]. Thus, the adenosine-mediated 
effects on the sleep-wake cycle are both neuron- and region-
dependent. 
PET may be applied to study the involvement of A1R in the 
regulation of human sleep. Increased expression of A1R in the 
human cortex after prolonged wakefulness has already been 
demonstrated [49]. Future PET studies could examine the effect of 
partial (REM) sleep deprivation in humans, and cerebral A1R 
expression in sleeping disorders like narcolepsy. 
3.2. Learning and Memory 
Acute stimulation of A1R by agonists at micromolar doses has 
been reported to severely impair both the acquisition and retention 
of memory in various animal and in vitro models, such as long-term 
potentiation in rat hippocampal slices [73], passive avoidance 
retention in mice [74,75], working memory in a three-panel test 
[76], and acquisition of conditional fear conditioning [77] or short-
term social memory in rats [78]. These cognitive deficits are 
attenuated, or abolished, when brain slices or experimental animals 
are pretreated with selective A1R antagonists such as DPCPX. 
Thus, activation of A1R in many regions of the CNS (hippocampus, 
ventral striatum, posterior cingulate cortex) may negatively 
modulate information processing in the brain and may impair 
memory retention [73-76]. Depending on the test setup (dose, 
region of administration, time of the day), acute administration of a 
selective A1R antagonist has either no effect or it can facilitate 
memory performance of rodents [75,78,79]. 
In contrast to acute administration, chronic administration of an 
A1R agonist (daily i.p. injections of CPA during a 9-day period) 
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results in facilitation of spatial learning and memory of mice tested 
in a Morris water maze. These improvements are probably related 
to downregulation of A1R [80].  
However, studies of the behavioral phenotype of mice lacking 
A1R have indicated that A1R are not essential for rodent learning. 
Such mice show normal motor coordination but reduced muscle 
strength. Overall spontaneous motor activity is similar to that of 
wild-type controls, but activity peaks during the light/dark cycle are 
flattened, which is consistent with A1R regulating the sleep-wake 
rhythm. A1R
-/-
 mice show enhanced aggression and decreased 
exploratory behavior indicating increased anxiety. However, their 
working memory in five different water maze tasks is not 
significantly impaired. The knockouts have a shorter lifespan than 
controls (LT50 reduced from 26 to 20 months), which suggests that 
A1R play an important protective role in mammalian tissues during 
aging [81,82]. In a follow-up study which included a six-arm radial 
tunnel maze test, A1R
-/-
 mice were found to display normal spatial 
learning but to habituate more slowly to the test environment [83]. 
Thus, stimulation of A1R may be required for habituation, i.e. 
suppression of the processing of irrelevant information. 
3.3. Effects of Ethanol 
Various effects of alcohol consumption appear to be mediated 
by adenosine and A1R. Ethanol metabolism in the liver causes 
formation of acetate, which circulates in the body at millimolar 
concentrations and is finally incorporated into acetyl-coenzyme A 
with concomitant production of AMP and adenosine [84]. Acute 
administration of ethanol results also in inhibition of the facilitated 
diffusion of nucleosides [84,85]. The inhibitory effect is specific for 
one particular subtype of ENT (ENT1) [86,87] and can be observed 
both in cultured cells [84,85,88] and in cerebellar synaptosomes 
[89,90]. Thus, ethanol augments the rate of adenosine formation 
and reduces adenosine uptake. Both mechanisms may increase the 
extracellular levels of adenosine.  
Initial attempts at measuring changes of adenosine levels within 
the brain after administration of ethanol or acetate were 
unsuccessful, probably because it is difficult to homogenize tissue, 
or to collect adenosine, while avoiding adenosine degradation 
[91,92]. Later analytical and microdialysis studies indicated that the 
levels of acetate and extracellular adenosine in cortical areas of rat 
brain are significantly increased (up to 4-fold) after administration 
of physiologically relevant doses of ethanol [93,94]. 
A functional relationship between ethanol and adenosine was 
suggested by the fact that dipyridamole, an inhibitor of ENT1, 
promotes ethanol-induced motor impairment (EIMI) [95]. Increases 
of EIMI were also noted after administration of the ENT inhibitor 
dilazep or the AR agonist R-PIA, whereas the AR antagonist 
theophylline suppressed EIMI [96] Several subsequent studies 
demonstrated that A1R agonists accentuate and A1R antagonists 
attenuate EIMI, when infused into the motor cortex [97] or striatum 
[98,99]. AR antagonists like theophylline or caffeine (Fig. 3), and 
lipophilic AR agonists like cyclohexyladenosine (CHA) modulate 
EIMI also after systemic administration. Experiments in which 
subtype-selective AR antagonists were administered either alone or 
in combination with agonists have indicated that the A1R subtype is 
involved in modulation of EIMI, although a contribution of A2R 
cannot be ruled out [97,99,100]. Co-administration of cAMP 
analogs, pertussis toxin or the (R)- and (S)-enantiomers of AR 
agonists with ethanol suggested involvement of G-protein-coupled 
A1R and adenylate cyclase [101,102]. The importance of A1R was 
proven by the fact that A1R antisense, applied orally, systemically 
or directly into the striatum or cerebellum reduced the regional A1R 
density and antagonized EIMI, whereas a mismatch control 
sequence had no effect [103,104]. A1R in the motor cortex, striatum 
and cerebellum, but not in hippocampus [98] appear to affect EIMI 
via adenosine-induced decreases in glutamate release [105,106] 
and/or changes of chloride conductance via chloride channels 
coupled to the GABA-benzodiazepine receptor complex [102,107].  
Besides playing a role in EIMI, adenosine is involved in other 
physiological responses related to the consumption of ethanol. The 
ENT1 inhibitor dipyridamole prolongs, and the AR antagonist 
theophylline reduces the duration of ethanol-induced sleep [95]. 
Ethanol and acetate also potentiate the anesthetic effect of 
sevoflurane and isoflurane through metabolically generated 
adenosine and stimulation of A1R [108-111]. In humans, the AR 
antagonist caffeine reverses most of the sedating effects of ethanol 
(sleepiness, lack of alertness, impaired memory) but not ethanol-
induced dizziness [112]. A recent study in rodents showed that 
ethanol promotes non-REM sleep but does not affect REM sleep. 
The somnogenic effect of ethanol is related to adenosine inhibition 
of wake-promoting neurons in the basal forebrain via A1R. Bilateral 
microinjections of the selective A1R antagonist DPCPX in this area 
reduce the effect of ethanol on non-REM sleep [113]. A study in 
which ethanol was administered to mice, either alone or in 
combination with selective AR agonists and antagonists, and 
animals were tested for anxiety in the elevated plus-maze, has 
indicated that activation of A1R also mediates the anxiolytic effect 
of ethanol [114]. 
Adenosine and A1R are not only involved in the motor 
impairing, sleep-promoting and sedating effects of ethanol, but also 
in counteracting the negative symptoms of ethanol withdrawal. 
Withdrawal signs in rats such as tremors and audiogenically 
induced seizures are suppressed by an A1R agonist (CCPA), and 
this beneficial effect is blocked after co-administration of an A1R 
antagonist (DPCPX) [115]. Other negative symptoms of ethanol 
withdrawal, such as hyperexcitability [116] and increased anxiety 
[117,118] are also ameliorated upon stimulation of A1R. AR 
antagonists (DPCPX, caffeine) are neurotoxic when administered 
during ethanol withdrawal, particularly in female mice, and these 
neurotoxic effects are reversed by an A1R agonist (CCPA). Sex 
differences observed for neurotoxicity of A1R antagonists during 
ethanol withdrawal are probably related to N-methyl-D-aspartic 
acid (NMDA)-receptor-mediated downstream signaling which is 
more pronounced in females than in males [119,120].  
Observed changes of A1R densities in rodent brain during 
ethanol exposure appear to be dependent on the experimental 
paradigm, the radioligand which is used for binding assays and the 
brain area that is studied. Using the agonist [
3
H]R-PIA, increases of 
Bmax without any change of Kd were noted in the cerebral cortex of 
rats, 15 min after administration of ethanol (1.5 g/kg, [96]). In a 
later study, the same authors noted that the observed increase (+ 
40.7%) is transient, receptor densities returning to the control value 
within 60 minutes [121]. Chronic administration of ethanol is also 
accompanied by an increased binding (+23%) of the agonist 2-
chloro-N6-cyclopentyladenosine ([
3
H]CCPA, Fig. 3) in rat cerebral 
cortex. This increase persists longer than the one observed after 
acute administration. Elevated receptor densities are observed 3, 12 
and 24 h after the last consumption of ethanol, but the ethanol effect 
disappears after 3 to 6 days [122]. Increased binding of the A1R 
agonist [
3
H]CHA was also noted in the cerebral cortex of mice 
following chronic administration of ethanol [123]. The increase is 
most pronounced after multiple episodes of ethanol withdrawal, and 
may be a compensatory inhibitory response to withdrawal seizures 
[124]. In contrast to the changes observed with A1R agonists, 
cortical binding of the A1R antagonist [
3
H]DPCPX is not affected 
by ethanol treatment [116,122]. Whereas most studies reported a 
transient increase of A1R agonist binding upon acute or chronic 
administration of ethanol, one old [95] and one recent [125] study 
reported decreases of A1R expression in some brain areas of rats. 
Decreased A1R expression in the wake-promoting basal forebrain 
may be related to insomnia associated with ethanol withdrawal 
[125].  
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Only a single PET study has examined changes of A1R 
expression after acute exposure of animals to ethanol [126]. In that 
study, Wistar rats were treated with a combination of ethanol and 
the AK inhibitor ABT-702, and scanned with the A1R ligand 
[
11
C]MPDX. A striking (40-45%) increase of tracer distribution 
volume and binding potential was noted in target areas such as 
hippocampus, striatum and cerebral cortex, 20-90 min after 
treatment. Additional PET studies could be performed to study the 
effect of ethanol only, either in rodents or in the human brain. 
3.4. Cerebral Ischemia  
Levels of extracellular adenosine in the brain are dramatically 
increased during ischemia. In patients with transient ischemic attack 
(TIA) or stroke, a rapid rise of the plasma concentration of 
adenosine occurs in peripheral venous blood, presumably because 
of spillover from the brain, and this increase persists for days (TIA) 
or weeks (stroke) [127]. Extracellular adenosine in the brain 
inhibits synaptic neurotransmission including the release of 
excitatory amino acids [128,129], leading to a better matching of 
energy demand and energy supply in ischemic areas and a reduction 
of delayed excitotoxicity [130]. Through A1R, adenosine promotes 
both the spontaneous electrical shutdown of the ischemic brain 
[131] and post-ischemic electrocortical burst suppression [132,133]. 
When levels of extracellular adenosine in mouse brain are reduced 
by transgenic overexpression of AK, postischemic cell death is 
increased [134]. 
The importance of A1R stimulation was also evident in studies 
regarding ischemic preconditioning. When neurons or living 
animals are exposed to a short period of sublethal ischemia, they 
are better protected to a subsequent serious ischemic insult. This 
beneficial effect of preconditioning disappears in the presence of an 
A1R antagonist like DPCPX, suggesting that A1R stimulation is 
involved [135-139]. The mechanisms underlying induction of rapid 
tolerance by a sublethal ischemic insult are not fully understood. 
Increases in protein kinase C activity, mitogen-activated protein 
(MAP) kinase activity, Akt activity, nitric oxide production and 
mitochondrial KATP channels may all be involved [135-139]. 
Activation of presynaptic K
+
 channels via stimulation of A1R may 
decrease evoked neurotransmitter release by hyperpolarization of 
the presynaptic membrane and thus improve resistance of the brain 
to ischemia.  
In various animal and in vitro models, acute administration of 
A1R agonists [140-143], inhibitors of adenosine uptake 
(propentofylline but not dipyridamole) [144], or inhibitors of AK 
[134] has been shown to result in protection against ischemic brain 
damage and reperfusion injury. Long-term treatment of gerbils with 
caffeine causes an upregulation of cerebral A1R (10-17%) and 
greater resistance of neurons to ischemia induced by bilateral 
carotid artery occlusion [145]. Increasing the binding of adenosine 
to A1R by administration of an allosteric enhancer also results in 
decreased brain damage after a hypoxic insult [146]. In contrast, 
acute administration of an A1R antagonist such as DPCPX 
aggravates the consequences of cerebral ischemia [141,142,147].  
Therapeutic application of A1R agonists in stroke patients may 
be complicated by the fact that such compounds can have 
diametrically opposite effects after chronic and acute 
administration. Acute treatment with an A1R agonist may reduce 
postischemic neuronal losses whereas chronic treatment with the 
same compound increases brain damage [142,148]. Other agonists 
are neuroprotective even during chronic treatment [149]. The 
underlying mechanisms are far from clear since the consequences 
of chronic administration of A1R ligands can not always be related 
to up- or downregulation of A1R [142]. 
Many studies have examined changes of A1R expression in the 
brain of experimental animals after cerebral ischemia. In most 
studies, rapid decreases of A1R mRNA and protein were observed 
during reperfusion [150-152] but in one study, decreases were 
noted at the mRNA but not the protein level [153]. These (slightly) 
discrepant findings may be due to the fact that different models of 
ischemia were employed and animals were examined at different 
intervals after the ischemic insult. Some changes appear only at 
intervals greater than 24 hours. Changes of A1R expression during 
ischemia have been little examined, as opposed to changes during 
reperfusion. In a single study, increases of A1R expression (at the 
mRNA and protein level) were noted during bilateral carotid artery 
ligation with a return to normal values immediately after 
reperfusion [154].  
An interesting study from Japan examined changes of cerebral 
A1R in cat brain following an ischemic insult, using PET and the 
radioligand 
11
C-MPDX. Decreases of A1R were noted, and the 






























































Fig. (3). AR ligands which are often used in binding studies. Top row: antagonists, bottom row: agonists. 
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insult. The extent of 
11
C-MPDX binding directly after reperfusion 
appeared to be a sensitive predictor of survival and disease 
symptoms during the follow-up period which lasted up to 2 months 
[155,156]. 
3.5. Epilepsy  
Adenosine inhibits the release of excitatory neurotransmitters 
and suppresses cellular activity and energy demand. Based on this 
evidence, it has been proposed that adenosine is a powerful 
endogenous anticonvulsant substance [157]. In amygdala-kindled 
rats, intracerebrally administered A1R agonists, such as 2-
chloroadenosine (Fig. 3) and PIA, could indeed suppress seizures 
[158-162]. These substances were also effective in other animal 
models of eplilepsy, such as entorhinal cortex kindling [163], 
piriform cortex kindling [164], hippocampal kindling [162,165], 
caudate nucleus kindling [162], intrahippocampal injection of 
kainic acid [166], intraperitoneal injection of pilocarpine [167] and 
hypoxia-induced convulsions [168]. The location of intracerebral 
administration is probably important for the therapeutic outcome 
[169]. In many studies, co-administration of A1R antagonists was 
shown to result in a reduction of the anticonvulsant effect, which 
indicates that the A1R subtype is involved in the beneficial action of 
the agonists.  
Inhibitors of the enzyme AK can be systemically administered 
and can increase extracellular adenosine levels in metabolically 
active brain regions. Such compounds show similar anticonvulsant 
actions as A1R agonists but lack the undesired peripheral side 
effects of these drugs [170]. AK is regionally overexpressed in 
epilepsy and this overexpression appears to contribute to the 
development and progression of seizure activity [134,171,172]. 
Local administration of adenosine by implanting encapsulated 
myoblasts could be a promising strategy for long term treatment of 
focal epilepsy [173] 
Further evidence for the involvement of the A1R in seizure 
suppression was obtained in animal models where A1R antagonists 
were administered. In a cat model of epilepsy (general seizures 
induced by intracortical injection of penicillin), the A1R antagonist 
CPT significantly prolonged the cycle period of seizures by 
increasing the duration of ictal discharge, in contrast to 7-
aminobutyric acid or opioid peptides [174]. Adenosine may 
accumulate during the ictal phase and be cleared during the 
interictal phase in status epilepticus. In a rat model of epilepsy 
(electrically induced seizures), secondary seizures were prolonged 
after administration of an A1R antagonist, and partial seizures were 
converted into generalized motor seizures [175]. In another rat 
model of epilepsy (i.p. administration of pilocarpine), the A1R 
antagonists DPCPX and 3,7-dimethyl-1-propargylxanthine 
(DPMX) showed proconvulsant effects, by significantly reducing 
the latency to develop status epilepticus [167]. Theophylline also 
lowered the seizure threshold and prolonged hyperthermia-induced 
seizures in juvenile rats [176]. Using a selective A1R antagonist 
(CPT), evidence was obtained that the inhibitory effect of low 
frequency stimulation of the perforant path on kindling acquisition 
in rats is mediated by stimulation of A1R [177]. 
Changes of cerebral A1R densities have been assessed both in 
animal models of epilepsy and in human brain post mortem. In a rat 
model of acute general seizure (i.p. injection of a convulsive dose 
of bicuculline), a widespread increase of A1R (
3
H-CHA binding) 
was noted, which was particularly evident in hippocampus, 
amygdala, substantia nigra and septum [178]. In a mouse model of 
general seizure (pentylentetrazol-induced convulsion) [179], A1R 
were upregulated in most brain areas but downregulated in the basal 
ganglia [180]. In tissue samples acquired from patients with 
temporal lobe epilepsy, a 48% increase of A1R density was 
observed in neocortex as compared to control samples from non-
epileptic subjects [181]. 
However, in another study on human temporal lobe epilepsy, 
A1R binding in temporal cortex was found to be reduced compared 
to normal postmortem controls [182]. A 15% decline of A1R 
density was also noted in the basal ganglia and thalamic nuclei of 
genetic absence epilepsy rats from Strasbourg compared to wild-
type littermates [183]. Even greater losses of A1R were noted in the 
hippocampus and cerebral cortex of kainate-treated, hippocampus-
kindled and amygdala-kindled rats, animal models of chronic 
epilepsy [184-187]. 
These conflicting results (either an upregulation or 
downregulation of A1R) may be related to differences in the 
experimental setup in animal models and differences in patient 
selection in human studies. An acute seizure, or a limited number of 
seizures may be accompanied by upregulation of A1R, or increased 
coupling of A1R to G-proteins [188,189], as a protective 
mechanism enhancing the anticonvulsant effect of endogenous 
adenosine. However, chronic seizures may cause a significant death 
of neurons with accompanying losses of A1R. The effects of partial 
and general seizures may also be different and the age (or 
developmental stage) of the subjects may affect the response of 
A1R to kindling [178,190].  
3.6. Traumatic Brain Injury 
Studies in A1R knockout mice have confirmed that this subtype 
plays an important role in suppressing neuronal hyperactivity. 
When normal and A1R knockout mice were subjected to controlled 
cortical impact – an animal model of traumatic brain injury (TBI) - 
seizure scores were much higher in the knockouts and only the 
knockout animals developed lethal status epilepticus [191]. 
Similarly, unilateral hippocampal kainate injection caused non-
convulsive status epilepticus in wild-type mice but severe 
convulsions and subsequent death of the animals in A1R knockouts 
[192]. The authors concluded that activation of A1R by adenosine 
is crucial in keeping an epileptic focus localized. Status epilepticus 
results in widespread adenosine release throughout the brain and 
suppression of the excitability of neurons remote from the epileptic 
focus via stimulation of A1R. In A1R knockout mice, this protective 
mechanism is lacking, so that severe convulsions and lethal status 
epilepticus can develop [192]. 
In another animal study on mild TBI, A1R knockout mice were 
shown to display a 20-50% enhanced microglial response compared 
to their wild-type littermates. Moreover, stimulation of A1R in BV-
2 (immortalized mouse microglia) cells inhibited microglial 
proliferation [193]. Thus, A1Rs appear to play an anti-inflammatory 
role in TBI-induced neuroinflammation.  
To the best of our knowledge, no PET studies on changes of 
A1R expression in epileptic patients or in animal models of epilepsy 
and TBI have been performed. Thus, there is considerable 
opportunity for imaging studies in this area. 
3.7. Neuroinflammation 
Besides its well-known function as an inhibitor of neuronal 
overactivity and its involvement in the regulation of sleep, 
adenosine has been proposed to act as an endogenous anti-
inflammatory agent [194]. In the CNS, A1Rs are expressed not only 
on neurons but also on glia [195]. A1R stimulation in microglia, the 
endogenous immune cells of the brain, may have both pro- and 
anti-inflammatory effects, depending on the presence or absence of 
other factors in the environment, such as phorbol 12-myristate 13-
acetate [196]. An early study reported that simultaneous activation 
of both A1R and A2AR stimulates microglial proliferation, whereas 
selective A1R or A2AR agonists when applied alone have no effect 
[195]. However, later studies have indicated that in most situations, 
A1R agonists suppress neuroinflammation. 
8    Current Medicinal Chemistry,  2011 Vol. 18, No. 2 Paul et al. 
In cultured astrocytes, CCPA enhanced the release of nerve 
growth factor [197], a compound which is essential for neuronal 
protection and a suppressor of neuroinflammation within the 
specific environment of the brain [198]. In plasmacytoid dendritic 
cells, adenosine has been suggested to play a dual role: first, 
chemotaxis to the site of inflammation is stimulated via A1R, then, 
the extent of the inflammatory response is limited by inhibition of 
the production of several cytokines such as interleukin-6, 
interleukin-12 and interferon- [199].  
The importance of A1R in controlling neuroinflammation was 
highlighted by studies of experimental allergic encephalomyelitis 
(EAE). Mice lacking A1R developed a much more severe, 
progressive-relapsing form of EAE than their wild-type littermates. 
Reduced densities of A1R in microglia of wild-type mice were 
observed during the neuro-inflammatory phase of EAE. 
Upregulation of A1R by treatment of normal mice with caffeine 
reduces EAE severity, and this beneficial effect of caffeine can be 
enhanced by concomitant administration of an A1R agonist [200]. 
In a rat model of neuroinflammation (EAE induced by guinea pig 
spinal cord homogenates), chronic caffeine treatment results in up-
regulation of A1R and attenuation of EAE pathology [201]. 
Experimentally induced neuroinflammation by chronic infusion of 
lipopolysaccharide (LPS) into the fourth ventricle of young rats, 
and natural microglia activation in aged rats are also attenuated 
after treatment of animals with caffeine [202]. In contrast to EAE 
(an animal model of chronic neuro-inflammation which is 
associated with a downregulation of A1R), acute inflammation of 
mouse brain after administration of LPS leads to increased A1R 
expression in cortical areas and this response is dependent on the 
transcription factor NF-kappaB [203]. 
An interesting study examined the role of A1R in brain tumors. 
Gliomas do not consist only of tumor cells but to a large extent (up 
to 30%) also of microglia and macrophages. Microglial cells 
accumulate particularly at the tumor rim. In the tumor environment, 
microglia acquires a different phenotype which is associated with 
expression of matrix metalloprotease II (MMP2). After acquisition 
of this novel phenotype, the microglial cells do not suppress but can 
actually promote tumor growth and invasion since these processes 
are MMP2-dependent. Experimental glioblastomas grew more 
vigorously and were associated with larger numbers of microglial 
cells in A1R knockout mice than in wild-type mice. In wild-type 
animals, A1R were up-regulated in microglia in contact with tumor 
cells but not in the rest of the brain. When glioma and microglia 
cells were cultured together in vitro, A1R agonists suppressed the 
growth of tumor cells, but in the absence of microglia, the same 
compounds stimulated tumor growth. Thus, adenosine attenuates 
glioblastoma growth, acting through microglial A1R [204]. 
Changes in cerebral A1R density caused by glioma invasion 
have been examined with the tracer [
18
F]CPFPX and PET, both in 
an animal model (F98 glioma-bearing rats) and in a patient with 
recurrent glioblastoma multiforme. In the animal model, A1R were 
also quantified by in vitro and in vivo autoradiography and 
immunohistochemical analysis. A1R were shown to be upregulated 
(by 36 to 46%) in a zone directly surrounding the tumor, and to be 
localized in activated astrocytes [205]. It would be interesting to 
study changes of A1R expression with microPET in animal models 
of neuroinflammation (e.g., the EAE model, the LPS model, or 
virally induced encephalitis). Such studies have not yet been 
reported.  
3.8. Human Diseases of the CNS  
3.8.1. Alzheimer’s Disease (AD) 
Since A1R signaling can be neuroprotective, many investigators 
examined changes of regional A1R density in human brain in 
neurodegenerative disorders. Initial autoradiographic studies were 
focused on AD and the hippocampus, a brain region involved in 
memory. A significant loss of A1R was observed in the CA1 (-47%) 
and dentate gyrus molecular layers (-46%) of the hippocampus but 
not in the CA3 [206]. Another study reported 40-60% decreases in 
all areas of the hippocampus, the most striking losses occurring in 
the molecular layer of the dentate gyrus [207]. Still another 
investigation reported substantial decreases in the dentate gyrus but 
A1R densities close to normal in CA1 and CA3 [208]. The former 
two investigations used the A1R agonist [
3
H]CHA whereas the last 
study employed the antagonist ligand [
3
H]CPDPX.  
Binding of an A1R agonist ([
3
H]R-PIA) and antagonist 
([
3
H]CPDPX) in the AD hippocampus were later directly 
compared. Both ligands detected prominent losses of A1R in the 
dentate gyrus. Decreased agonist binding was observed in CA1 and 
outer layers of the parahippocampal gyrus, whereas losses of 
antagonist binding were noted in the subiculum and CA3. These 
decreases reflected reductions of receptor number (Bmax) rather than 
reductions of the affinity (KD) of A1R for the radioligands [209] 
In the striatum of AD patients, 30-36% losses of A1R were 
noted both in the caudate nucleus and putamen, and these losses 
appeared to parallel the decrease of choline acetyl transferase [210].  
An immunohistochemical study from Spain showed that A1R 
are redistributed in the hippocampus and cerebral cortex of AD 
patients in comparison to age-matched controls. A1R accumulate in 
degenerating neurons and are co-localized with ß-amyloid in senile 
plaques and with tau in neurons with tau deposition. Studies in the 
human neuroblastoma cell line SH-SY5Y indicated that A1R 
stimulation increases the production of soluble forms of amyloid 
precursor protein, and the phosphorylation and translocation of tau 
to the cytoskeleton. By inhibiting the deposition of amyloid and 
enhancing the translocation of tau, A1R stimulation may slow down 
the process of neurodegeneration [211].  
An upregulation of A1R was detected in the frontal cortex of 
AD patients (both at early and advanced stages of the disease), 
using quantitative autoradiography and the radioligand [
3
H]DPCPX 
[212]. However, a PET study in AD patients and elderly normal 
subjects indicated significant decreases of the binding potential of 
[
11
C]MPDX in the temporal and medial temporal cortices and 
thalamus of the patients with no significant change in other areas of 
the brain [213] (Fig. 4). Discrepant findings in human studies may 
be related to the facts that different patient groups were selected 
(early vs. late onset AD), different brain regions were examined, 
and different techniques were used for quantification 
(immunohistochemistry, ligand binding). Moreover, a transient 
upregulation of A1R may be followed by an eventual receptor loss. 
3.8.2. Pick’s and Creutzfeld-Jakob Disease 
In the frontal cortex of individuals with Pick’s [214] and 
Creutzfeldt-Jakob [215] disease, similar increases of A1R density 
were noted as in patients with AD, using quantitative 
autoradiography and [
3





F]CPFPX in such patients have been reported.  
3.8.3. Multiple Sclerosis (MS) 
Several studies have reported changes of AR signaling in 
patients with MS. Plasma levels of TNF- in such patients are 
significantly higher and levels of adenosine are significantly lower 
than in control subjects. Stimulation of peripheral blood 
mononuclear cells (PBMC) with a selective A1R agonist (R-PIA) 
inhibits the mitogen-stimulated production of TNF- in healthy 
subjects but not in MS patients, whereas the opposite is observed 
for the mitogen-stimulated production of interleukin-6 [216]. A1R 
densities in PBMC and in brain tissue from MS-patients are 
significantly decreased (by 53% and 49%, respectively) compared 
to age-matched controls [217]. Thus, both A1R densities and the 
coupling of A1R to cytokine signaling systems appear to be altered 
in MS. However, no PET studies with A1R ligands have been 
performed in this patient group. 
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3.8.4. Parkinson’s Disease 
In the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse 
model of Parkinson’s disease, the drug paeoniflorin proved capable 
of reducing neurodegeneration and inhibiting neuroinflammation by 
activation of A1R [218]. Thus, modulation of neuroinflammation 
via A1R may be a novel approach towards treatment of 
neurodegenerative disease. 
Deep brain stimulation (DBS) is frequently applied for the 
treatment of movement disorders and may also benefit individuals 
with psychiatric disease. Recently, it was shown that the 
mechanism underlying the beneficial effect of DBS is a local 
release of ATP which is extracellularly metabolized to adenosine 
and suppresses tremor via A1R. The effect of DBS can be mimicked 
by intrathalamic infusion of A1R agonists. On the other hand, AR 
antagonists like caffeine can trigger or exacerbate essential tremor 
[219]. 
3.8.5. Schizophrenia 
A partial loss of A1R during birth and a corresponding 
reduction of the control of dopamine activity in later life has been 
proposed to play a role in the inhibitory deficit in schizophrenia 
[220,221]. Association between a single nucleotide polymorphism 
of the A1R gene (rs3766553) and schizophrenia was indeed noted in 
a Japanese population [222]. PET studies of cerebral A1R in 
patients with schizophrenia have not yet been performed. 
4. PHARMACODYNAMIC STUDIES 
4.1. A1R (ant)agonists 
PET has important applications in the study of 
pharmacodynamics, i.e. assessment of the effects of drugs in the 
healthy and diseased body, including their mechanisms of action 
and the relationship between drug concentration and effect. During 
the development of CNS drugs, PET is often used to measure the 
dose-dependent occupancy of target receptors in the human brain 
by a non-radioactive test compound. PET is also capable of 
measuring the metabolic response of tissues to treatment 
quantitatively, repeatedly and noninvasively, both in experimental 
animals and humans. 
Only a few PET studies regarding A1R occupancy by cold 
antagonists have been reported in the literature. An interesting 
paper from Germany showed that the binding of 
18
F-CPFPX in rat 
brain is reduced after treatment of animals with caffeine, shortly 
before injection of the tracer. At a dose of 4 mg/kg, corresponding 
to consumption of three to four cups of coffee by a human being, 
tracer binding was strongly (ca. 50%) suppressed, suggesting ~70% 
receptor occupancy [223]. Another study showed that 
18
F-CPFPX 
bound to A1R in human brain can be dose-dependently displaced by 
injecting non-radioactive CPFPX [224]. A microPET study from 
our own group has indicated that A1R in rat brain are almost 
completely occupied after administration of DPCPX (3 mg/kg, i.p.), 
20 min before injection of 
11
C-MPDX [126]. 
Thus, the dose-dependent occupancy of A1R in the brain by test 
drugs may be assessed by PET. Dose-dependent effects of A1R 
agonists (or AK inhibitors, see 4.2) on organ metabolism could be 
assessed as well, using the radiolabeled glucose analog [
18
F]FDG, 
but such studies have not yet been reported.  
4.2. AK Inhibitors 
AK regulates intra- and extracellular adenosine concentrations 
by phosphorylation of adenosine to AMP. Although ADA also 
removes adenosine by converting it to inosine, the reaction 
catalyzed by AK is the most important pathway of adenosine 
removal under physiological conditions [225]. Since the major 
adenosine-specific nucleoside carrier acts as a non-concentrative, 
bi-directional, facilitated diffusion transporter, adenosine transport 
is driven by the concentration gradient across the cell membrane. 
Inhibition of AK raises intracellular adenosine, diminishes the 
concentration gradient and decreases the cellular uptake of 
adenosine, resulting in increased extracellular adenosine 
concentrations, particular under pathophysiological conditions and 
in tissues or brain regions where the formation of adenosine is 
increased by net catabolism of ATP [226-228]. An in vivo study in 



















Fig. (4). PET scans of the brain of an Alzheimer disease patient, made with [18F]FDG (top row) and [11C]MPDX (bottom row). Distribution patterns of 
[18F]FDG and [11C]MPDX are similar, but a statistical parametric analysis revealed that [11C]MPDX PET was not coupled with hypometabolism in the 
posterior cingulate gyrus. 
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extracellular adenosine during excitotoxic insults in the striatum but 
do not affect striatal adenosine levels in vehicle-treated controls 
[228]. Thus, AKIs represent a strategy for potentiating the 
protective actions of endogenous adenosine during tissue trauma 
[229]. This therapeutic approach may be advantageous in cases 
where not a single subtype (e.g., A1R) but rather a multiplicity of 
AR subtypes should be stimulated for the beneficial effect [230].  
Three applications of AKIs have been proposed. First, 
intrathecally administered AR agonists [231-233] and AKIs [232-
234] have antinociceptive effects in experimental animals. These 
effects are counteracted by selective A1R antagonists but not by 
A2AR antagonists suggesting involvement of A1R stimulation 
[228,232,235,236]. Novel AKIs such as ABT-702 and A-286501 
can also be given subcutaneously or orally and are then effective in 
animal models of acute, inflammatory and neuropathic pain 
[235,237-239]. Substantial interest in the use of AKIs was raised by 
the fact that these compounds can be equally effective as morphine 
for the suppression of pain but show less potential to develop 
tolerance [238,240,241]. The use of AKIs rather than AR agonists 
allows an adequate separation between antinociceptive and motor-
impairing effects [242].  
Second, AR agonists and AKIs have shown anti-inflammatory 
efficacy in various animal models of acute and chronic 
inflammation [238,239,243-248].  
A third potential application of AKIs is in the treatment of 
epilepsy. These compounds suppress seizures in rodent models, 
such as the bicuculline-induced seizure [249] and the maximal 
electroshock [170,250,251] model, presumably via an interaction of 
adenosine with cerebral A1R. For that reason and because 
upregulation of the enzyme AK is involved in epileptogenesis 
[171], AKIs are considered promising anticonvulsants 
[170,252,253]. 
If a ligand could be developed of which the binding is sensitive 
to competition by endogenous adenosine, PET imaging could be 
applied to assess changes of extracellular adenosine induced by 
AKIs.  
CONCLUSION 
The purine nucleoside adenosine and its A1R are implied in 
many physiological functions, such as regulation of the sleep-wake 
cycle, aggression, and anxiety, habituation of animals to a novel 
environment, protection of cells against the negative consequences 
of hypoxia and ischemia. Adenosinergic signaling is also implied in 
ethanol-induced motor impairment, and withdrawal symptoms after 
ethanol abuse. Stimulation of A1R has anticonvulsant and anti-
inflammatory actions. Changes of A1R expression have been noted 
in animal models of epilepsy, the micro-environment of brain 
tumors, and various diseases of the human CNS such as AD, Pick’s 
disease, Creutzfeld-Jakob disease, MS and schizophrenia. Since 
appropriate ligands for PET imaging of A1R are now available, PET 
can be applied to elucidate the role of A1R in the normal and 
diseased human brain and to study the pharmacodynamics of A1R 
agonists and AKI.  
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